Morphic Announces that AbbVie Exercises License Option to αvβ6 Integrin Inhibitor Program, Including MORF-720, for Fibrotic Diseases

NEXT STORY
Phase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary Endpoint Reducing Seizure Frequency in Children with Dravet Syndrome or Lennox-Gastaut Syndrome
PREV STORY
Global Amoxicillin Market Is Expected to Reach USD 5.03 Billion by 2027 : Fior Markets
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Alzamend Neuro™ Appoints New CEO, Bio-Pharma Executive Stephan Jackman

Salt Lake City, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Alzamend Neuro™, Inc. (Alzamend™ or ...

author_avatar
NASDAQ Market News

Nirsevimab reduced respiratory syncytial virus infections requiring medical care in healthy premature infants in Phase 2b trial

author_avatar
NASDAQ Market News

Turning Point Therapeutics Presents Updated Preliminary Clinical Data for Repotrectinib and Elzovantinib (TPX-0022) at 2021 AACR-NCI-EORTC Conference and Provides Regulatory Updates

author_avatar
NASDAQ Market News